Nicola Valeri
尼古拉·瓦莱里
MD, PhD
Professor of Molecular Pathology; Consultant Medical Oncologist分子病理学教授;顾问医学肿瘤科医生
👥Biography 个人简介
Nicola Valeri, MD, PhD is Professor of Molecular Pathology at The Institute of Cancer Research (ICR) and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust in London. He is a leading European authority on mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) as biomarkers for immunotherapy, particularly in gastrointestinal cancers. His laboratory has made seminal contributions to the biology of dMMR in colorectal and gastric cancer, including characterizing mechanisms of secondary MMR loss and POLE/POLD1 mutations as alternative hypermutation pathways. Valeri's translational work has contributed to standardizing MSI-H/dMMR testing across IHC and molecular methods in European clinical practice and has informed the integration of universal dMMR screening in colorectal cancer pathology workflows. He has also been a leader in liquid biopsy and ctDNA research, developing approaches for monitoring minimal residual disease and treatment response in gastrointestinal cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
MSI-H/dMMR Testing Standardization in Europe
Led comparative studies of MSI PCR, IHC, and NGS methods in colorectal and gastric cancer, contributing evidence that formed the basis for European consensus guidelines on universal dMMR/MSI testing in colorectal cancer and pan-tumor dMMR screening to identify pembrolizumab-eligible patients.
POLE/POLD1 Mutations as Ultramutated Immunotherapy Biomarkers
Characterized POLE and POLD1 exonuclease domain mutations as a distinct hypermutation mechanism beyond MSI-H, demonstrating that POLE-mutant tumors with extreme TMB are highly responsive to checkpoint inhibition, establishing POLE mutation testing as a complementary biomarker to MSI-H.
ctDNA for dMMR Colorectal Cancer Monitoring
Developed and validated ctDNA-based liquid biopsy approaches for monitoring minimal residual disease and detecting emergent resistance to immunotherapy in dMMR colorectal cancer, informing adaptive treatment strategies.
Representative Works 代表性著作
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science (2017)
Co-authored landmark study demonstrating dMMR as a pan-tumor biomarker for pembrolizumab response across 12 cancer types, providing the scientific basis for the first tissue-agnostic FDA approval of pembrolizumab.
POLE and POLD1 mutations in endometrial and colorectal cancers
Nature Reviews Clinical Oncology (2021)
Comprehensive review defining POLE/POLD1 mutations as a distinct ultramutated biomarker category with high immunotherapy responsiveness, separate from and complementary to MSI-H/dMMR.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 尼古拉·瓦莱里 的研究动态
Follow Nicola Valeri's research updates
留下邮箱,当我们发布与 Nicola Valeri(The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust)相关的新研究或访谈时,我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment